Today, Type 2 diabetes is 24 times more prevalent than Type 1. The rise in rates of obesity and incidence of Type 2 diabetes are related and require new approaches, according to the researchers, who believe the liver may hold the key to innovative new treatments.
"All current therapeutics for Type 2 diabetes primarily aim to decrease blood glucose. So, they are treating a symptom, much like treating the flu by decreasing the fever," said the senior author. "We need another breakthrough."
In two newly published papers in Cell Reports, the researchers outline a new target for Type 2 diabetes treatment.
"Obesity is known to be a cause of Type 2 diabetes and, for a long time, we have known that the amount of fat in the liver increases with obesity," the author said. "As fat increases in the liver, the incidence of diabetes increases."
This suggested that fat in the liver might be causing Type 2 Diabetes, but how fat in the liver could cause the body to become resistant to insulin or cause the pancreas to over-secrete insulin remained a mystery, the author said.
The authors focused on fatty liver, measuring neurotransmitters released from the liver in animal models of obesity, to better understand how the liver communicates with the brain to influence metabolic changes seen in obesity and diabetes.
"We found that fat in the liver increased the release of the inhibitory neurotransmitter Gamma-aminobutyric acid, or GABA," the author said. "We then identified the pathway by which GABA synthesis was occurring and the key enzyme that is responsible for liver GABA production - GABA transaminase."
A naturally occurring amino acid, GABA is the primary inhibitory neurotransmitter in the central nervous system, meaning it decreases nerve activity.
Nerves provide a conduit by which the brain and the rest of the body communicate. That communication is not only from the brain to other tissues, but also from tissues back to the brain, the author explained.
"When the liver produces GABA, it decreases activity of those nerves that run from the liver to the brain. Thus, fatty liver, by producing GABA, is decreasing firing activity to the brain," the author said. "That decrease in firing is sensed by the central nervous system, which changes outgoing signals that affect glucose homeostasis."
To determine if increased liver GABA synthesis was causing insulin resistance, the authors pharmacologically inhibited liver GABA transaminase in animal models of Type 2 diabetes.
"Inhibition of excess liver GABA production restored insulin sensitivity within days," said the lead author on the papers. "Longer term inhibition of GABA-transaminase resulted in decreased food intake and weight loss."
Researchers wanted to ensure the findings would translate to humans. they identified variations in the genome near GABA transaminase that were associated with Type 2 diabetes. The researchers showed that in people with insulin resistance, the liver more highly expressed genes involved in GABA production and release.
The findings are the foundation of clinical trial currently underway. The trial will investigate the use of a commercially available Food and Drug Administration-approved inhibitor of GABA transaminase to improve insulin sensitivity in people who are obese.
"A novel pharmacological target is just the first step in application; we are years away from anything reaching the neighborhood pharmacy," the author said. "The magnitude of the obesity crisis makes these promising findings an important first step that we hope will eventually impact the health of our family, friends and community."
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00677-X
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fhepatocyte-membrane&filter=22
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fa-critical-role-of&filter=22
Role of GABA in type 2 diabetes
- 2,489 views
- Added
Edited
Latest News
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Mapping microbiome in metas…
By newseditor
Posted 22 Apr
Full-length mRNA packaged i…
By newseditor
Posted 22 Apr
Glucose-sensing mechanism t…
By newseditor
Posted 21 Apr
Other Top Stories
Curing drug-resistant infections without antibiotics
Read more
Engineered enzyme eliminates nicotine addiction in preclinical tests
Read more
Linking genes to social behavior!
Read more
Unmasking blood doping in athletes - Micro RNA to differentiate old…
Read more
Brain signaling in aggressive behavior identified!
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Neuronal activity rapidly r…
By newseditor
Posted 22 Apr
A perspective on muscle phe…
By newseditor
Posted 22 Apr
Foxp1 suppresses cortical a…
By newseditor
Posted 22 Apr
Single-cell long-read seque…
By newseditor
Posted 22 Apr
Unlocking potential: the ro…
By newseditor
Posted 22 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar